Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 11;20:1093. doi: 10.1186/s12885-020-07569-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 7 — BRF2 alterations alter overall patient survival in an age-dependent manner. Using the cBioPortal [26], we queried a subset of the Invasive Breast Cancer Data Set (TCGA, Firehose Legacy) [28, 34, 35] for BRF2 alterations, restricting our analysis to complete patient data sets which included mutations, CNA, and mRNA microarray expression data (960 patients). Overall survival Kaplan-Meier estimate was determined comparing patients overall survival status, by month, in patients with alterations (red line) to those without alterations (blue line) in BRF2 analyzed by age of diagnosis: (a) 35 < X < 40, (b) 40 < X < 45, (c) 45 < X < 50, and (d) 50 < X < 55. Logrank p-value for each overall survival Kaplan-Meier estimated is noted. The Breast Invasive Carcinoma data set analyzed is available at the cBioPortal (www.cbioportal.org). Queries of the cBioPortal were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020